Xu et al. (2017) demonstrated that MYD88 mutations were significantly more common in DLBCL patients who were refractory to chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) compared with DLBCL patients who were chemo-sensitive (15%). This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.